What were the key takeaways from Alcon's earnings call?

What guidance did Alcon's management provide for the next earnings period?

What factors drove the changes in Alcon's revenue and profit?

What is the revenue and EPS growth rate for Alcon year over year?

What is Alcon's latest dividend and current dividend yield?

What does Alcon do and what are its main business segments?

What were the key takeaways from Alcon’s earnings call?

Did Alcon beat or miss consensus estimates last quarter?

- **Revenue Growth**: Q4 up 7% to $2.7B, driven by Surgical (+6%) and Vision Care (+7%). 2026 guided at 5-7% growth.
- **Innovation Impact**: Unity VCS/CS equipment sales +18%, Tryptyr achieves 3% U.S. market share in 5 months. TOTAL30 multifocal toric expands multifocal segment.
- **Margin Expansion**: 2026 core EPS growth 9-12%, supported by $100M cost savings. Gross margin stable at 62.5%, operating margin to improve 70-170bps.
- **Strategic Focus**: Accelerating launches (Vivity 2.0, Truel+) and optimizing cost structure to drive long-term margin expansion.

**【CEO Summary Section】**
- **Innovation Drives Growth**: Highlighted advancements in surgical platforms (Unity VCS/CS), IOLs (PanOptix Pro, Truel+), and Vision Care (TOTAL30 multifocal toric, PRECISION7). Unity VCS won a major industry award for its efficiency and safety.
- **IOL Momentum**: PanOptix Pro stabilized U.S. trifocal share, while Truel+ targets monofocal plus segment. Vivity 2.0 launch in 2027 aims to enhance near vision without compromising outcomes.
- **Dry Eye Leadership**: Tryptyr achieved 3% U.S. market share in 5 months, with high refill rates. Systane Pro launched with a direct-to-consumer campaign.
- **Market Trends**: Global cataract volumes grew 3% Q4, AT-IOL penetration up 90bps. Contact lens market grew 4%, driven by U.S. innovation.

**【CFO Financial Commentary】**
- **Q4 Financials**: Revenue $2.7B (+7% YoY), Core EPS $0.78. Surgical franchise up 6%, Vision Care up 7%. Gross margin 62.5% (-50bps YoY due to tariffs). Operating margin 19% (-160bps YoY).
- **2026 Outlook**: 5-7% revenue growth, 9-12% EPS growth. $100M annualized cost savings from efficiency initiatives. Free cash flow expected to exceed 100% of core net income.
- **Leverage Strategy**: Balancing R&D investments (9% of sales) with SG&A leverage. 2026 tariff impact assumed at 15%.

**【Q&A Highlights】**
- **Guidance Confidence**: 3-4% market growth assumption reflects cautious optimism. Equipment (Unity) and Tryptyr expected to drive first-half growth, Vision Care in second-half.
- **Unity Momentum**: 18% Q4 equipment growth, 3,000+ annual placements targeted. Surgeon feedback highlights efficiency and safety.
- **Tryptyr Trajectory**: Tracking ahead of expectations, with $250-400M peak sales potential. Expanding prescriber base and Medicare coverage.
- **Refractive Strategy**: WaveLight Plus LASIK and ICL pipeline to address white spaces. Focus on premium outcomes and patient loyalty.


Alcon Inc. (ALC) Q4 2025 Earnings Call Transcript

- **Revenue Beat Expectations**: Q3 $2.6B (+5% YoY), driven by Surgical and Vision Care growth.
- **Unity VCS Leadership**: 1,200 placements YTD, with 2026 equipment growth acceleration.
- **Profit Margin Challenges**: 2026 tariffs to pressure margins, offset by product innovation.
- **Strategic Acquisitions**: STAAR deal highlights Alcon's refractive-surgical integration strategy.


**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue of $2.6 billion (+5% YoY), driven by Surgical (+5%) and Vision Care (+5%).
- **Unity VCS Momentum**: 1,200 placements YTD, with focus on training and workflow integration for efficiency gains.
- **Product Launch Success**: PanOptix Pro stabilizing U.S. trifocal IOL share, Tryptyr early adoption strong with prescriber uptake.
- **Acquisition Update**: STAAR Surgical deal remains attractive, though not critical to growth.

**【CFO Financial Commentary】**
- **Margins Under Pressure**: Core operating margin 20.2% (-60bps YoY) due to tariffs, R&D, and SG&A investments.
- **Free Cash Flow**: $1.2B YTD, supporting $550M shareholder returns (shares buyback + dividends).
- **Tariff Impact**: Q4 tariff-related charges to rise, with $50-100M incremental 2026 impact offset by FX and cost actions.
- **2026 Outlook**: 4-6% top-line growth, with margin expansion via product mix and cost control.

**【Q&A Highlights】**
- **Unity VCS**: Order book strong, placements pacing deliberate to ensure adoption.
- **Market Dynamics**: U.S. cataract volumes improving but still below historical 4% trend.
- **Tryptyr**: Early prescriber enthusiasm, though audited data lags digital platform adoption.
- **Competitive Landscape**: Intensified implantables competition, but Alcon maintains majority share.


Alcon Inc. (ALC) Q3 2025 Earnings Call Transcript

- **Product Expansion**: $1.5B STAAR acquisition and Valeda launch position Alcon in high-growth refractive and dry AMD markets.
- **Financial Resilience**: Q2 core EPS $0.76, 681M free cash flow, with 4-5% FY25 revenue growth despite $100M tariff headwind.
- **Strategic Momentum**: Unity VCS adoption on track, Tryptyr launch underway, and 12-15% EPS CAGR reaffirmed for long-term growth.

**【CEO Summary Section】**
- **Product Launches & Acquisitions**: Highlighted new product launches (Unity VCS, PanOptix Pro, Tryptyr) and acquisitions (STAAR Surgical, LumiThera) to expand into high-growth markets like refractive surgery and dry AMD. STAAR acquisition valued at $1.5B, expected to close in 6-12 months.
- **Market Dynamics**: Surgical market growth soft at 2% YTD (vs. historical 4%), driven by procedural delays. Vision Care and Ocular Health segments showed resilience with 5% and 2% growth, respectively.
- **Strategic Focus**: Emphasized innovation (e.g., photobiomodulation in Valeda) and global expansion, particularly in China, despite macroeconomic headwinds.

**【CFO Financial Commentary】**
- **Q2 Financials**: Revenue $2.6B (+3% YoY), core gross margin 62.2%, free cash flow $681M. Core EPS $0.76, in line with prior year.
- **Tariff Impact**: $100M annualized tariff impact, partially offset by FX and operational actions. Updated FY25 guidance: $10.3-10.4B revenue, 4-5% growth, 19.5-20.5% operating margin.
- **Cash Deployment**: $287M returned to shareholders (Q2), with focus on disciplined cost management and R&D investment.

**【Q&A Highlights】**
- **Unity VCS Adoption**: Over 1,000 leads post-launch, targeting 3,000 installations over 10 years. Deliberate ramp to ensure surgeon training and workflow efficiency.
- **IOL Share Stabilization**: U.S. share stabilized sequentially, but international pressure persists due to competitive launches.
- **Tariff Mitigation**: Primarily FX-driven, with limited supply chain changes. Full year impact expected at $100M.
- **Tryptyr Launch**: Late July launch with strong professional education and reimbursement strategy; peak sales potential $250-400M.
- **Long-Term Growth**: Reaffirmed 12-15% EPS CAGR target, driven by operating leverage and new product contributions.

Alcon Inc. (ALC) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: Q1 2025 at $2.5B (+3%), with 6-7% full-year guidance driven by Unity VCS, PanOptix Pro, and PRECISION7 launches.
- **Product Innovation**: Launches of advanced surgical systems and IOLs position Alcon for long-term growth in eye care.
- **Tariff Resilience**: $80M annual tariff impact expected, but operational actions and currency tailwinds to fully offset.
- **Strategic Acquisitions**: Aurion Biotech acquisition targets $0.5B+ peak sales for corneal endothelial therapy.
- **Market Challenges**: U.S. surgical market softness, but international growth and diversification mitigate risk.

**【CEO Summary Section】**
- Q1 2025 sales of $2.5 billion with 3% growth, driven by product launches and geographic diversification.
- Launched Unity VCS (combined vitreoretinal and cataract surgery console) and PanOptix Pro (next-gen trifocal IOL) in the U.S. and Japan.
- Acquired majority stake in Aurion Biotech for its corneal endothelial cell therapy, targeting $0.5 billion+ peak sales.
- Faced U.S. surgical market softness but maintained core operating margin of 20.8%.
- Tariffs pose $80M annual cost headwind, but mitigation strategies (pricing, manufacturing shifts) expected to offset impact.

**【CFO Financial Commentary】**
- Surgical franchise up 2% YoY, with strong growth in China and international markets offsetting U.S. weakness.
- Vision care sales +3%, driven by PRECISION1 and TOTAL30 families (+4% contact lens growth).
- Ocular health +2% due to Systane Pro and price increases.
- Full-year guidance updated to $10.4-10.5B revenue (6-7% growth) and core EPS $3.05-3.15, reflecting $0.10 impact from Aurion acquisition.
- Tariffs expected to pressure Q3/Q4, but operational actions and currency tailwinds to fully offset.

**【Q&A Highlights】**
- **Growth Acceleration**: Back-half 2025 growth driven by Unity VCS, PanOptix Pro, and PRECISION7 launches. Q2 expected to be mid-single-digit, with high-single-digit in Q3/Q4.
- **U.S. Cataract Market**: Softness due to surgeon productivity challenges, but Unity VCS efficiency gains expected to help.
- **Contact Lenses**: PRECISION7 gaining traction in reusable market ($3.8B TAM). Legacy product declines offset by new innovation.
- **Aurion Impact**: 80bps margin pressure in 2025, mostly R&D expenses. Phase 3 trial for corneal endothelial therapy to begin late 2025.
- **Tariff Mitigation**: Advocating for medtech exemption; $80M annual impact assumes current tariffs persist. 2026+ impact dependent on policy stability.

Alcon Inc. (ALC) Q1 2025 Earnings Call Transcript

- **Record Financials**: 2024 sales $9.8B (+6%), EPS $3.05 (+16%), free cash flow $1.6B.
- **Innovation-Driven Growth**: New products (UNITY VCS, PRECISION7) set for H2 2025 launches, with China VBP driving Surgical growth.
- **Margin Expansion**: 2025 core EPS $3.15-3.25 (+8-11%), operating margin 21-22% with back-half leverage.
- **Key Risks**: US ATIOL competitive pressure, tariff exposure, and new product adoption variability.

**【CEO Summary Section】**
- **2024 Yearly Performance**: Total sales of $9.8 billion (+6% YoY), core diluted EPS of $3.05 (+16%), and record free cash flow of $1.6 billion.
- **Product Innovations**: Launches include UNITY VCS phaco-vitrectomy device, PanOptix Pro IOL, PRECISION7 contact lenses, and SYSTANE Pro dry eye drops. UNITY VCS received FDA clearance and CE Mark pending, with commercial launch in May 2025.
- **Market Dynamics**: Global cataract procedures grew mid-single-digits, driven by international markets. US market growth slower due to competitive trialing and sampling. Contact lens retail market up mid-single-digits, driven by pricing and lens trade-up.

**【CFO Financial Commentary】**
- **Q4 2024 Results**: Sales $2.5 billion (+6% YoY). Surgical revenue $1.4 billion (+5% YoY), Vision Care $1.1 billion (+7% YoY). Core gross margin 62.7% (+70bps), operating margin 20.1% (+130bps) due to improved product mix and cost control.
- **2025 Guidance**: Full-year revenue $10.2-10.4 billion (6-8% CAGR). Core EPS $3.15-3.25 (+8-11% CAGR). Operating margin 21-22%, with investments front-loaded in R&D and new product launches.
- **Financial Highlights**: Record free cash flow ($1.6B YoY), dividend increase to CHF0.28/share, and $750M share buyback program approved.

**【Q&A Key Takeaways】**
- **US ATIOL Market**: Competitive trialing impacting share, but China VBP program driving growth (+180bps ATIOL penetration YoY). PanOptix Pro launch in May 2025 expected to stabilize US share.
- **Margins & Growth**: 2025 operating margin expansion back-half loaded due to R&D investments. Equipment sales (e.g., UNITY VCS) expected to accelerate in H2, offsetting Surgical margin pressure.
- **China Strategy**: VBP participation boosting IOL volumes, with Vivity and PanOptix leading growth. China VBP benefits expected in Q2 2025.
- **Dry Eye Pipeline**: AR-15512 (512) launch H2 2025 pending FDA approval, targeting $1.4B Rx dry eye market with faster onset and lipid replenishment.
- **Tariff Risks**: Diversified manufacturing (US, Europe, Singapore) mitigates supply chain disruptions, but tariffs on imported components remain a risk.

Actual				0.4514	-0.2017	0.3898	0.4217	0.4755	0.556	0.5305	0.5665	0.7296	0.6194	0.4772	0.4257	0.6799	0.6773	0.6389	0.7317	0.7835	0.7023	0.8433	0.7085	0.6922	0.77	0.7906	0.7623
Forecast				0.347	-0.094	0.2223	0.414	0.4425	0.4492	0.4952	0.4987	0.5392	0.576	0.4787	0.4252	0.6096	0.6347	0.6443	0.7009	0.7225	0.7219	0.7543	0.6979	0.7291	0.7304	0.769	0.7805
Surprise	0.00%	0.00%	0.00%	+30.09%	-114.57%	+75.35%	+1.86%	+7.46%	+23.78%	+7.13%	+13.60%	+35.31%	+7.53%	-0.31%	+0.12%	+11.53%	+6.71%	-0.84%	+4.39%	+8.44%	-2.72%	+11.80%	+1.52%	-5.06%	+5.42%	+2.81%	-2.33%

ALC

ALC fundamentals

ALC Q4 2025 Earnings

Earnings Call

You can ask Aime

ALC

ALC fundamentals

ALC Q4 2025 Earnings

Earnings Call

ALC Earnings Call Summary for Q4/20259:00 AM on Feb 25, 2026

ALC Earnings Call Summary for Q3/20258:00 AM on Nov 12, 2025

ALC Earnings Call Summary for Q2/20258:00 AM on Aug 20, 2025

ALC Earnings Call Summary for Q1/20258:00 AM on May 14, 2025

ALC Earnings Call Summary for Q4/20248:00 AM on Feb 26, 2025

You can ask Aime